{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:34Z","timestamp":1792004374959,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s15010-024-02425-4","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T10:33:43Z","timestamp":1731926023000},"page":"1061-1068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In vitro activity of ceftazidime-avibactam\/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains"],"prefix":"10.1007","volume":"53","author":[{"given":"Niklas","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Jantsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annerose","family":"Serr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan F.","family":"Ehrentraut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Mollitor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar T.R.","family":"Hischebeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"issue":"7","key":"2425_CR1","doi-asserted-by":"publisher","first-page":"e0200020","DOI":"10.1128\/AAC.02000-20","volume":"65","author":"KM Kazmierczak","year":"2021","unstructured":"Kazmierczak KM, et al. Epidemiology of Carbapenem Resistance determinants identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017. Antimicrob Agents Chemother. 2021;65(7):e0200020.","journal-title":"Antimicrob Agents Chemother"},{"key":"2425_CR2","doi-asserted-by":"crossref","unstructured":"Sridhar S, et al. Antimicrobial-resistant bacteria in international travelers. Curr Opin Infect Dis; 2021.","DOI":"10.1097\/QCO.0000000000000751"},{"key":"2425_CR3","doi-asserted-by":"crossref","unstructured":"Sandfort M et al. Increase in NDM-1 and NDM-1\/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022. Euro Surveill, 2022. 27(50).","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200926"},{"key":"2425_CR4","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.2147\/IDR.S234610","volume":"12","author":"P Dadgostar","year":"2019","unstructured":"Dadgostar P. Antimicrobial Resistance: implications and costs. Infect Drug Resist. 2019;12:3903\u201310.","journal-title":"Infect Drug Resist"},{"issue":"1036","key":"2425_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1098\/rstb.1980.0049","volume":"289","author":"RP Ambler","year":"1980","unstructured":"Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321\u201331.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2425_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jgar.2021.06.011","volume":"26","author":"E Cercenado","year":"2021","unstructured":"Cercenado E, et al. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDEROWT2014-2018 studies in Spain. J Glob Antimicrob Resist. 2021;26:292\u2013300.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"2425_CR7","doi-asserted-by":"publisher","first-page":"115420","DOI":"10.1016\/j.diagmicrobio.2021.115420","volume":"101","author":"K Kristof","year":"2021","unstructured":"Kristof K, et al. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014\u20132017 and 2018. Diagn Microbiol Infect Dis. 2021;101(1):115420.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"2425_CR8","doi-asserted-by":"publisher","first-page":"e180212","DOI":"10.1590\/0074-02760180212","volume":"113","author":"A Santos","year":"2018","unstructured":"Santos A, et al. What are the advantages of living in a community? A microbial biofilm perspective! Mem Inst Oswaldo Cruz. 2018;113(9):e180212.","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"2425_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang Z, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177\u201392.","journal-title":"Biotechnol Adv"},{"issue":"3","key":"2425_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"9276","key":"2425_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(01)05321-1","volume":"358","author":"PS Stewart","year":"2001","unstructured":"Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135\u20138.","journal-title":"Lancet"},{"issue":"8","key":"2425_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","volume":"19","author":"EB Breidenstein","year":"2011","unstructured":"Breidenstein EB, de la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8):419\u201326.","journal-title":"Trends Microbiol"},{"key":"2425_CR13","doi-asserted-by":"crossref","unstructured":"Codjoe FS, Donkor ES. Carbapenem resistance: Rev Med Sci (Basel), 2017. 6(1).","DOI":"10.3390\/medsci6010001"},{"issue":"1","key":"2425_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","volume":"11","author":"FC Tenover","year":"2022","unstructured":"Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022;11(1):811\u20134.","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"2425_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11318430-000000000-00000","volume":"70","author":"C Bebrone","year":"2010","unstructured":"Bebrone C, et al. Current challenges in antimicrobial chemotherapy: focus on ss-lactamase inhibition. Drugs. 2010;70(6):651\u201379.","journal-title":"Drugs"},{"issue":"4","key":"2425_CR16","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1128\/AAC.04218-14","volume":"59","author":"P Levasseur","year":"2015","unstructured":"Levasseur P, et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized beta-lactamases. Antimicrob Agents Chemother. 2015;59(4):1931\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"39","key":"2425_CR17","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"DE Ehmann","year":"2013","unstructured":"Ehmann DE, et al. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem. 2013;288(39):27960\u201371.","journal-title":"J Biol Chem"},{"issue":"Suppl1","key":"2425_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.37201\/req\/s01.11.2021","volume":"34","author":"M Matesanz","year":"2021","unstructured":"Matesanz M, Mensa J. Ceftazidime-Avibactam. Rev Esp Quimioter. 2021;34(Suppl1):38\u201340.","journal-title":"Rev Esp Quimioter"},{"issue":"3","key":"2425_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clinthera.2016.01.018","volume":"38","author":"R Sharma","year":"2016","unstructured":"Sharma R, Park TE, Moy S. Ceftazidime-Avibactam: a novel Cephalosporin\/beta-Lactamase inhibitor combination for the treatment of resistant gram-negative organisms. Clin Ther. 2016;38(3):431\u201344.","journal-title":"Clin Ther"},{"key":"2425_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jgar.2022.01.025","volume":"29","author":"TM Rawson","year":"2022","unstructured":"Rawson TM, et al. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing enterobacterales infection. J Glob Antimicrob Resist. 2022;29:558\u201362.","journal-title":"J Glob Antimicrob Resist"},{"key":"2425_CR21","doi-asserted-by":"crossref","unstructured":"Intra J et al. Antimicrobial resistance patterns of Enterobacter cloacae and Klebsiella aerogenes strains isolated from clinical specimens: a twenty-year Surveillance Study. Antibiot (Basel), 2023. 12(4).","DOI":"10.3390\/antibiotics12040775"},{"issue":"1","key":"2425_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"SM Drawz","year":"2010","unstructured":"Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160\u2013201.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"2425_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: second-generation beta-Lactam\/beta-Lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234\u201341.","journal-title":"Clin Infect Dis"},{"key":"2425_CR24","doi-asserted-by":"crossref","unstructured":"Karlowsky JA et al. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by Clinical Laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother, 2017. 61(9).","DOI":"10.1128\/AAC.00472-17"},{"issue":"12","key":"2425_CR25","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1128\/AAC.44.12.3322-3327.2000","volume":"44","author":"N Masuda","year":"2000","unstructured":"Masuda N, et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000;44(12):3322\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2425_CR26","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, et al. Efficacy of Ceftazidime-Avibactam Plus Aztreonam in patients with bloodstream infections caused by Metallo-beta-lactamase-producing enterobacterales. Clin Infect Dis. 2021;72(11):1871\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2425_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/ejhpharm-2021-002772","volume":"29","author":"A Pelaez Bejarano","year":"2022","unstructured":"Pelaez Bejarano A, et al. Successful treatment of Verona integron-encoded metallo-beta-lactamase-producing Klebsiella pneumoniae infection using the combination of ceftazidime\/avibactam and aztreonam. Eur J Hosp Pharm. 2022;29(2):113\u20135.","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"2425_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","volume":"37","author":"MD Gonzalez","year":"2017","unstructured":"Gonzalez MD, et al. Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a Collection of beta-lactam-resistant gram-negative Bacteria. Ann Lab Med. 2017;37(2):174\u20136.","journal-title":"Ann Lab Med"},{"key":"2425_CR29","doi-asserted-by":"crossref","unstructured":"Humphries RM et al. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against Beta-lactam-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother, 2017. 61(12).","DOI":"10.1128\/AAC.01858-17"},{"issue":"7","key":"2425_CR30","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.21037\/jtd-20-417","volume":"12","author":"T Lupia","year":"2020","unstructured":"Lupia T, et al. New cephalosporins for the treatment of pneumonia in internal medicine wards. J Thorac Dis. 2020;12(7):3747\u201363.","journal-title":"J Thorac Dis"},{"key":"2425_CR31","doi-asserted-by":"crossref","unstructured":"Sader HS et al. Antimicrobial activity of Ceftazidime-Avibactam tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. Medical Centers, 2013 to 2016. Antimicrob Agents Chemother, 2017. 61(11).","DOI":"10.1128\/AAC.01045-17"},{"issue":"2","key":"2425_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijantimicag.2019.05.001","volume":"54","author":"F Schaumburg","year":"2019","unstructured":"Schaumburg F, et al. Comparison of methods to analyse susceptibility of German MDR\/XDR Pseudomonas aeruginosa to ceftazidime\/avibactam. Int J Antimicrob Agents. 2019;54(2):255\u201360.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"2425_CR33","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/jac\/dky267","volume":"73","author":"KM Kazmierczak","year":"2018","unstructured":"Kazmierczak KM, et al. In vitro activity of ceftazidime\/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother. 2018;73(10):2777\u201381.","journal-title":"J Antimicrob Chemother"},{"key":"2425_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18\u201327.","journal-title":"J Glob Antimicrob Resist"},{"issue":"11","key":"2425_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/psp4.12452","volume":"8","author":"A Chauzy","year":"2019","unstructured":"Chauzy A, et al. Semimechanistic Pharmacodynamic modeling of Aztreonam-Avibactam combination to Understand its antimicrobial activity against Multidrug-Resistant Gram-negative Bacteria. CPT Pharmacometrics Syst Pharmacol. 2019;8(11):815\u201324.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"2425_CR36","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/jac\/dks079","volume":"67","author":"DM Livermore","year":"2012","unstructured":"Livermore DM, et al. Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline\u2009+\u2009avibactam (NXL104). J Antimicrob Chemother. 2012;67(6):1354\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2425_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/psp4.12159","volume":"6","author":"S Sy","year":"2017","unstructured":"Sy S, et al. Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms. CPT Pharmacometrics Syst Pharmacol. 2017;6(3):197\u2013207.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2425_CR38","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2147\/IDR.S173804","volume":"11","author":"SD Atkin","year":"2018","unstructured":"Atkin SD, et al. Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. Infect Drug Resist. 2018;11:1499\u2013510.","journal-title":"Infect Drug Resist"},{"issue":"6","key":"2425_CR39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ijantimicag.2019.02.022","volume":"53","author":"R Zamudio","year":"2019","unstructured":"Zamudio R, et al. Phylogenetic analysis of resistance to ceftazidime\/avibactam, ceftolozane\/tazobactam and carbapenems in piperacillin\/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients. Int J Antimicrob Agents. 2019;53(6):774\u201380.","journal-title":"Int J Antimicrob Agents"},{"key":"2425_CR40","doi-asserted-by":"crossref","unstructured":"Davido B et al. Ceftazidime-Avibactam and Aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by Metallo-beta-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2017. 61(9).","DOI":"10.1128\/AAC.01008-17"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02425-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02425-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02425-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:54:24Z","timestamp":1749016464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02425-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2425"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02425-4","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}